Combined modality treatment for rectal cancer

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Multimodal therapy, including surgery, radiation therapy (RT), and chemotherapy, is crucial for localized rectal cancer.
• Neoadjuvant approaches (preoperative treatment) are increasingly utilized to improve surgical outcomes and reduce treatment toxicity.
• 5-fluorouracil (5-FU)-based chemotherapy with RT is the current standard adjuvant therapy.

Purpose of the Study:

• To review advancements in integrating RT and chemotherapy with surgery for rectal cancer.
• To highlight the evolution towards neoadjuvant strategies in rectal cancer management.
• To discuss ongoing investigations into novel therapeutic agents and biologic modulators.

Main Methods:

• Review of current literature on multimodal treatment for localized rectal cancer.
• Analysis of the evolution from adjuvant to neoadjuvant therapy paradigms.
• Identification of emerging chemotherapeutic agents and biologic modulators in clinical investigation.

Main Results:

• Significant improvements in sphincter preservation, tumor control, and reduced treatment morbidity have been achieved.
• Neoadjuvant combinations of RT and chemotherapy demonstrate enhanced efficacy compared to historical adjuvant approaches.
• Ongoing research focuses on novel agents to further optimize treatment outcomes.

Conclusions:

• Integrated multimodal therapy, particularly neoadjuvant approaches, has significantly advanced rectal cancer care.
• The standard of care involves 5-fluorouracil (5-FU)-based chemotherapy with RT, but novel agents are under active investigation.
• Future research aims to refine neoadjuvant strategies and incorporate novel therapies for improved patient outcomes.